ReviewCancers2026
Ultrasound-Guided Axillary Management in Early-Stage Breast Cancer: From Diagnosis to De-Escalation.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Axillary lymph node management in early-stage breast cancer has undergone a fundamental transformation over the past three decades, shifting from routine radical clearance to precision-guided de-escalation. Ultrasound (US) has emerged as the central imaging modality in this paradigm shift, serving as the first-line tool for preoperative nodal assessment, guidance for biopsy and clip placement, monitoring of response to neoadjuvant chemotherapy (NAC), and localization of marked nodes for targeted axillary dissection (TAD). This review systematically examines the evolution of axillary management in early-stage breast cancer through a US-centric lens. We summarize the historical transition from Halstedian axillary lymph node dissection (ALND) to sentinel lymph node biopsy (SLNB), critically appraise the landmark trials-Z0011, AMAROS, OTOASOR, and SOUND-that have progressively de-escalated axillary surgery, and detail the role of US in preoperative staging (including conventional B-mode, superb microvascular imaging, contrast-enhanced US, elastography, and AI-assisted diagnostics), US-guided biopsy and node marking, and post-NAC TAD. We further explore the integration of US with liquid biopsy, multigene profiling, and molecular subtype-guided systemic therapy to enable individualized decision-making. Finally, we propose a stepwise US-centric clinical algorithm and discuss future directions, including AI-powered real-time interpretation, imaging-omics, and US-guided targeted therapy. This review provides a comprehensive framework for incorporating ultrasound as a key component of multidisciplinary decision-making-alongside pathological, surgical, radiotherapeutic, and molecular inputs-in contemporary axillary management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.